Tags

Type your tag names separated by a space and hit enter

A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency.
J Womens Health (Larchmt) 2012; 21(6):674-82JW

Abstract

BACKGROUND

S-equol, a metabolite of the soy isoflavone daidzein, has been proposed as having potential for relief of menopausal symptoms. This study compared the efficacy of the natural S-equol supplement, SE5-OH, with isoflavones for relieving hot flashes and other menopausal symptoms.

METHODS

An 8-week randomized, double-blind, active comparator trial with SE5-OH was conducted in postmenopausal women (aged 45-65 years), who experienced ≥5 hot flashes/day. Participants (n=102) were assigned to one of four treatment groups: 10 (n=24), 20 (n=27), or 40 (n=25) mg S-equol/day or soy isoflavones (n=26). Participants recorded their hot flash frequency and rated their menopause symptom severity.

RESULTS

Reductions in hot flash frequency at week 8 were similar for all treatment groups. However, based on analyses of the cumulative effect for the 8-week period, 40 mg/day S-equol had a greater reduction of hot flash frequency compared to isoflavones (p=0.021). A subgroup analysis further indicated that for subjects with >8 hot flashes/day at baseline, 20 and 40 mg/day S-equol were superior to isoflavones in reducing hot flash frequency (p=0.045 and p=0.001, respectively). In addition, 10 and 20 mg/day S-equol improved muscle and joint pain score compared with isoflavones (p=0.003 and p=0.005, respectively).

CONCLUSIONS

S-equol, 10 mg/day, appears to be as effective as soy isoflavones at reducing hot flash frequency and more effective for relieving muscle and joint pain in postmenopausal women. S-equol, ≥20 mg/day, alleviates hot flashes to a greater extent than soy isoflavones in those women who experience >8 hot flashes/day.

Authors+Show Affiliations

Pharmavite LLC, Northridge, CA 91604, USA. bjenks@pharmavite.net

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22409590

Citation

Jenks, Belinda H., et al. "A Pilot Study On the Effects of S-equol Compared to Soy Isoflavones On Menopausal Hot Flash Frequency." Journal of Women's Health (2002), vol. 21, no. 6, 2012, pp. 674-82.
Jenks BH, Iwashita S, Nakagawa Y, et al. A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency. J Womens Health (Larchmt). 2012;21(6):674-82.
Jenks, B. H., Iwashita, S., Nakagawa, Y., Ragland, K., Lee, J., Carson, W. H., ... Uchiyama, S. (2012). A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency. Journal of Women's Health (2002), 21(6), pp. 674-82. doi:10.1089/jwh.2011.3153.
Jenks BH, et al. A Pilot Study On the Effects of S-equol Compared to Soy Isoflavones On Menopausal Hot Flash Frequency. J Womens Health (Larchmt). 2012;21(6):674-82. PubMed PMID: 22409590.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency. AU - Jenks,Belinda H, AU - Iwashita,Soh, AU - Nakagawa,Yasushi, AU - Ragland,Karen, AU - Lee,Jennifer, AU - Carson,William H, AU - Ueno,Tomomi, AU - Uchiyama,Shigeto, Y1 - 2012/03/12/ PY - 2012/3/14/entrez PY - 2012/3/14/pubmed PY - 2012/9/21/medline SP - 674 EP - 82 JF - Journal of women's health (2002) JO - J Womens Health (Larchmt) VL - 21 IS - 6 N2 - BACKGROUND: S-equol, a metabolite of the soy isoflavone daidzein, has been proposed as having potential for relief of menopausal symptoms. This study compared the efficacy of the natural S-equol supplement, SE5-OH, with isoflavones for relieving hot flashes and other menopausal symptoms. METHODS: An 8-week randomized, double-blind, active comparator trial with SE5-OH was conducted in postmenopausal women (aged 45-65 years), who experienced ≥5 hot flashes/day. Participants (n=102) were assigned to one of four treatment groups: 10 (n=24), 20 (n=27), or 40 (n=25) mg S-equol/day or soy isoflavones (n=26). Participants recorded their hot flash frequency and rated their menopause symptom severity. RESULTS: Reductions in hot flash frequency at week 8 were similar for all treatment groups. However, based on analyses of the cumulative effect for the 8-week period, 40 mg/day S-equol had a greater reduction of hot flash frequency compared to isoflavones (p=0.021). A subgroup analysis further indicated that for subjects with >8 hot flashes/day at baseline, 20 and 40 mg/day S-equol were superior to isoflavones in reducing hot flash frequency (p=0.045 and p=0.001, respectively). In addition, 10 and 20 mg/day S-equol improved muscle and joint pain score compared with isoflavones (p=0.003 and p=0.005, respectively). CONCLUSIONS: S-equol, 10 mg/day, appears to be as effective as soy isoflavones at reducing hot flash frequency and more effective for relieving muscle and joint pain in postmenopausal women. S-equol, ≥20 mg/day, alleviates hot flashes to a greater extent than soy isoflavones in those women who experience >8 hot flashes/day. SN - 1931-843X UR - https://www.unboundmedicine.com/medline/citation/22409590/A_pilot_study_on_the_effects_of_S_equol_compared_to_soy_isoflavones_on_menopausal_hot_flash_frequency_ L2 - https://www.liebertpub.com/doi/full/10.1089/jwh.2011.3153?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -